Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Specifics - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is claimed that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5].

Core Viewpoint - The article discusses ongoing legal issues faced by uniQure N.V. related to a securities class action lawsuit, highlighting significant criticisms from FDA officials regarding the company's gene therapy candidate AMT-130 and its clinical study practices [1][3][5]. Group 1: Legal Proceedings - A securities class action lawsuit has been filed against uniQure, representing investors who acquired shares between September 24, 2025, and October 31, 2025 [1][6]. - The deadline for investors to apply as Lead Plaintiff in the pending class action is April 13, 2026 [1][6]. Group 2: FDA Criticism - An FDA official labeled uniQure's AMT-130 as a "failed therapy," accusing the company of presenting a "distorted or manipulated comparison" in its clinical studies [3][7]. - The FDA has not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, indicating a lack of regulatory consensus [8]. Group 3: Allegations Against uniQure - The lawsuit alleges that uniQure misrepresented its interactions with the FDA and failed to disclose critical information regarding the approval of its pivotal study design [5][6]. - Allegations include mischaracterization of sham surgeries, denial of prior agreements with the FDA, and misleading investors about the timeline for a Biologics License Application (BLA), which resulted in a 49% stock drop after the lack of FDA agreement was revealed [7][8].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who acquired its securities during the specified class period, alleging misrepresentation and failure to disclose critical information regarding the company's drug development process [1][3]. Group 1: Lawsuit Details - The lawsuit targets investors who purchased uniQure securities from September 24, 2025, to October 31, 2025 [1][2]. - Investors have until April 13, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure misrepresented the approval status of its Pivotal Study for the drug AMT-130, which is intended to treat Huntington's disease [3]. - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies [3]. Group 3: Stock Impact - Following the disclosure on November 3, 2025, that the FDA did not agree with the use of Phase I/II data for BLA submission, uniQure's stock plummeted over 49%, from $67.69 per share on October 31, 2025, to $34.29 per share [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is claimed that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the April 13, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought shares during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 13, 2026, to serve as lead plaintiff [2] - The lawsuit claims that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study and Biologics License Application (BLA) timeline [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]

Core Viewpoint - The Gross Law Firm is notifying shareholders of uniQure N.V. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Pivotal Study and Biologics License Application timeline [1][3]. Group 1: Allegations - The complaint alleges that during the class period from September 24, 2025, to October 31, 2025, uniQure's management issued materially false and/or misleading statements [3]. - It is claimed that the design of uniQure's Pivotal Study was not fully approved by the FDA, which was not disclosed to investors [3]. - The likelihood of a delay in the Biologics License Application timeline due to the need for additional studies was downplayed, leading to a lack of reasonable basis in the company's statements about its business and prospects [3]. Group 2: Class Action Details - Shareholders are encouraged to register for the class action by April 13, 2026, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A securities class action lawsuit has been filed against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, due to alleged misrepresentations regarding the drug AMT-130, which is being developed for Huntington's Disease [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the drug AMT-130 [4]. - Investors who acquired uniQure ordinary shares during the specified period are eligible to join the class action [1][2]. - The deadline to file as a lead plaintiff is April 13, 2026, and participation does not require serving as a lead plaintiff [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless there is a recovery [3]. - The firm has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the April 13, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 13, 2026, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is claimed that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4][5]. Group 1: Lawsuit Details - The lawsuit was filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [2][7]. - The case is titled Scocco v. uniQure N.V., et al., and was filed in the United States District Court for the Southern District of New York [2]. - Investors have until April 13, 2026, to move the Court to serve as lead plaintiff for the class [3][9]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [4][5]. - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that uniQure downplayed the likelihood of needing to delay its BLA timeline due to additional studies [5]. - The lawsuit claims that these misrepresentations led to a significant drop in the company's share price when the truth about the BLA submission was revealed [6][8]. Group 3: Impact on Share Price - Following the revelation on November 3, 2025, uniQure's share price fell by $33.40, or over 49%, from $67.69 to $34.29 per share [6][8]. Group 4: Investor Actions - Investors who have lost money on their investment in uniQure are encouraged to contact Kessler Topaz Meltzer & Check, LLP for legal rights and recovery options [3][10]. - The lead plaintiff process allows investors to represent the class in litigation, with no obligation to take action if they choose not to [9].

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding its gene therapy drug AMT-130 and its clinical trial results [1][4][6]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease (HD) [3]. - The company's leading drug candidate is AMT-130, aimed at slowing the progression of HD [3]. Lawsuit Details - The class action lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1]. - The class period for affected investors is from September 24, 2025, to October 31, 2025 [4]. - Investors have until April 13, 2026, to apply to be lead plaintiffs in the case [2][8]. Allegations - The lawsuit alleges that uniQure made materially false and misleading statements about its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [4][6]. - Specific allegations include: 1. The design of the Pivotal Study was not fully approved by the FDA [6]. 2. The likelihood of needing to delay the BLA submission was downplayed despite purportedly successful trial results [6]. 3. Defendants' statements lacked a reasonable basis regarding the company's business and operations [6]. Impact on Share Price - On November 3, 2025, uniQure disclosed that the FDA did not agree that the data from the Phase I/II studies were adequate for BLA submission, leading to a significant drop in share price [7]. - The share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [7].